HCA Healthcare stock gains as BofA lifts target ahead ex-dividend date
Published on 09/16/2026 at 10:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
HCA Healthcare stock (ISIN US40412C1018) last closed at USD 425.49 on the New York Stock Exchange as of September 14, 2026, giving the hospital operator a market capitalization of about USD 92.4 billion. As MarketScreener reported on September 14, 2026, Bank of America lifted its price target on HCA Healthcare stock to USD 450 from USD 425 while maintaining a positive stance on the shares, and investors are also eyeing a new USD 0.78 quarterly dividend per share that goes ex-dividend on September 16, 2026.
Analyst boost from Bank of America
According to MarketScreener on September 14, 2026, BofA Securities reiterated its Buy rating on HCA Healthcare stock and increased its price target from USD 425 to USD 450, signaling confidence in the company’s earnings and cash flow profile. The new target implies an upside of about 5.8 percent from the recent closing price of USD 425.49, giving investors a concrete benchmark for the bank’s constructive view on the shares.
The same MarketScreener transcript ties the rating to management’s commentary at the 2026 Jefferies Healthcare Services and Technology Conference, where executives underlined resilient demand for hospital services and ongoing strategic investments. As Quartr summarizes from the conference, HCA Healthcare reaffirmed guidance for the second half of the year that incorporates a USD 1.0 billion to USD 1.2 billion negative impact from insurance exchanges, partially offset by USD 300 million to USD 500 million in net supplemental payment benefits.
Recent earnings show double-digit growth
HCA Healthcare’s latest reported quarter offers context for the upgraded price target. According to Quartr, revenue in the second quarter of 2026 rose 8.7 percent year on year, while earnings per share increased by 11 percent over the same period, confirming that the business is expanding at a healthy pace. The margin picture is more mixed: Quartr notes that uninsured admissions surged in Q2 2026, which put some pressure on profitability even as overall volumes grew.
The first quarter of 2026 was also solid. As Quartr reports, HCA Healthcare generated Q1 2026 revenue of USD 19.1 billion, up 4.3 percent compared with the prior-year quarter, and net income of USD 1.62 billion, while management reaffirmed its guidance range for the full year. The combination of mid-single-digit revenue growth in Q1 2026 and high-single-digit growth in Q2 2026 shows an accelerating top line, which helps explain why Bank of America felt comfortable raising its target.
Ex-dividend date adds income angle
In addition to the analyst support, investors in HCA Healthcare stock are watching a fresh dividend catalyst. According to Moomoo on September 14, 2026, HCA Healthcare shares trade ex-dividend on September 16, 2026, for a quarterly payment of USD 0.78 per share to shareholders of record on that date, with the dividend scheduled to be paid on September 30, 2026. At the recent closing price of USD 425.49, the single-quarter payout of USD 0.78 represents a dividend yield of about 0.18 percent for that period, while the annualized dividend would be USD 3.12 if maintained.
For income-focused investors, the ex-dividend date can be a short-term trading trigger, but the more important point is the company’s ability to sustain and potentially grow its payout over time. The combination of double-digit earnings growth in Q2 2026 and ongoing share repurchases and capital investments, as highlighted during the Jefferies conference, supports the case that HCA Healthcare can fund dividends, capacity expansion and technology upgrades simultaneously.
Valuation and market reaction
Several valuation frameworks suggest that HCA Healthcare stock trades below intrinsic value despite the strong run-up into mid-September 2026. On September 15, 2026, GuruFocus published a discounted cash flow analysis that put HCA Healthcare’s earnings-based intrinsic value at USD 784.86 per share and its free cash flow-based intrinsic value at USD 666.74, compared with a current trading level of USD 425.49. That implies a margin of safety of about 45.8 percent on the earnings-based model and 36.2 percent on the FCF-based model.
GuruFocus also cited a GF Value of USD 460.55 for HCA Healthcare stock, which still stands above the recent price and aligns with the more moderate upside suggested by sell-side analysts. Meanwhile, as of mid-September 2026, the INDmoney data referenced in the earlier Ad-hoc summary indicated that the stock was about 23.5 percent below its 52-week high of USD 556.52 and roughly 20.2 percent above its 52-week low of USD 353.99, placing the current price in the middle of its recent trading range and suggesting room both for recovery and for volatility.
Analyst consensus and key risks
Beyond BofA Securities, the broader analyst community remains constructive on HCA Healthcare stock. According to MarketBeat on September 16, 2026, fourteen analysts currently rate the shares Buy, eight rate them Hold and one assigns a Sell rating, resulting in a consensus rating of Moderate Buy. MarketBeat reports a consensus target price of USD 462.64, which stands modestly above both the recent closing price and BofA’s USD 450 target, indicating that most analysts see further upside but not an extreme mispricing.
However, HCA Healthcare is not without risks, and these are part of the investment narrative. The guidance discussed at the Jefferies conference and reported by Quartr explicitly incorporates a USD 1.0 billion to USD 1.2 billion negative impact from exchanges in the second half of the year. While supplemental payments of USD 300 million to USD 500 million are expected to offset part of this headwind, policy changes and payer mix remain key variables for hospital earnings.
Strategic moves and long-term growth
Strategic initiatives complement the near-term numbers for HCA Healthcare. On September 15, 2026, HCA Healthcare announced that it had completed the acquisition of The College of Health Care Professions, a provider of allied health education. As HCA Healthcare states in its release, the deal is intended to support talent development and expand access to training programs for healthcare professionals across the company’s network.
For investors, the acquisition is relevant because staffing and workforce development are central constraints in the hospital industry. By investing in its own pipeline of health care professionals, HCA Healthcare aims to reduce reliance on expensive agency labor and improve operating efficiency over time. That strategic rationale complements the earnings growth seen in Q1 and Q2 2026 and feeds into the optimistic tone of both BofA’s rating and the GuruFocus valuation work.
Stock price and trading context
Per recent price data, HCA Healthcare stock closed at USD 425.49 on the NYSE on September 14, 2026, after trading between USD 420.00 and USD 433.80 during that session and moving about 5.8 percent higher over the preceding seven days as of September 15, 2026. As of that mid-September 2026 snapshot, the shares stood roughly 23.5 percent below their 52-week high of USD 556.52 and about 20.2 percent above the 52-week low of USD 353.99, with a total market capitalization of approximately USD 92.4 billion.
Key facts on HCA Healthcare stock
- Company: HCA Healthcare Inc.
- ISIN: US40412C1018
- Ticker: HCA
- Trading venue: NYSE
- Price (as of September 14, 2026): 425.49 USD
- Market capitalization: 92,400,000,000 USD (as of September 14, 2026)
- Sector / Industry: Healthcare / Hospitals
- Index membership: S&P 500
